Basic science researchers at the Johns Hopkins University School of Medicine are advancing heart health research by finding ...
As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...
DD01 is a liver-targeted, long-acting, dual GLP-1/glucagon receptor agonist previously shown to rapidly resolve hepatic steatosis, improve glycemic control, and reduce body weight in subjects with ...
ACCP Position Statement: "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists"
ACCP is a non-profit association providing accredited Continuing Education, publications and career-enhancing opportunities to clinical pharmacology healthcare professionals. We sell different ...
For more information about INDIGO's GLP-1R, GIPR, and Glucagon Receptor Reporter Assays and other products and services, visit ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback